BioSpace News Archive

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3rd in Boston, MA, and the Benchmark Company Discovery One-on-One Conference on Wednesday, December 4th in New York, NY.

Jopari Solutions, Inc., a leader in providing connectivity and innovative healthcare attachment management, flexible medical payments products and integrated eBill compliance for Workers’ Compensation and Auto Medical markets, is proud to announce the appointment of John Gilmartin as Chief Operating Officer

To help support cancer caregivers, the American Cancer Society (ACS) has created a Caregiver Support Video Series that can answer caregivers’ most-asked questions and address their biggest concerns

Marmon Holdings, Inc., a Berkshire Hathaway company, today announced it has acquired a majority interest in the Colson Medical Companies, a global provider of specialty medical devices, from Colson Associates, Inc.

The Brooklyn Hospital Center is a full-service community teaching hospital located in Brooklyn, New York.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the third quarter ended September 30, 2019 and provided a business update.

Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, announced that Dr. Chad E. Beyer, Senior Vice President of R&D, will share clinical findings from Promentis’ Phase 2A clinical trial at the 10th annual CNS Summit in Boca Raton, FL.

Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it will report its financial results for the third quarter and nine months ended September 30, 2019, on Monday, November 11, after the market close.

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced two senior leadership changes to further build the company’s capabilities as it approaches topline results from the pivotal Phase 3 NEPTUNE trial for OV101 in Angelman syndrome, expected in mid-2020.

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, announced today the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective October 31, 2019.